Abstract
The analysis of positron emission tomography (PET) scan image is challenging due to a high level of noise and a low resolution and also because differences between healthy and demented are very subtle. High dimensional classification methods based on PET have been proposed to automatically discriminate between normal control group (NC) patients and patients with Alzheimer’s disease (AD), with mild cognitive impairment (MCI), and mild cognitive impairment converting to Alzheimer’s disease (MCIAD ) (a group of patients that clearly degrades to AD). We developed a voxelbased method for volumetric image analysis. We performed 3 classification experiments AD vs CG, AD vs MCI, MCIAD vs MCI. We will also give a small demonstration of the presented method on a set of face images. This method is capable to extract information about the location of metabolic changes induced by Alzheimer’s disease that directly relies statistical features and brain regions of interest (ROIs). We produce “maps” to visualize the most informative regions of the brain and compare them with voxel-wise statistics. Using the mean intensity of about 2000 6 × 6 × 6mm patches, selected by the extracted map, as input for a classifier we obtain a classification rate of 95.5%.
Keywords: AD, Alzheimer’s disease, classification, Computer-aided diagnosis, machine learning, MCI, PET scan, random forest.
Current Alzheimer Research
Title:Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization
Volume: 13 Issue: 5
Author(s): V. Vigneron, A. Kodewitz, A. M. Tome, S. Lelandais and E. Lang
Affiliation:
Keywords: AD, Alzheimer’s disease, classification, Computer-aided diagnosis, machine learning, MCI, PET scan, random forest.
Abstract: The analysis of positron emission tomography (PET) scan image is challenging due to a high level of noise and a low resolution and also because differences between healthy and demented are very subtle. High dimensional classification methods based on PET have been proposed to automatically discriminate between normal control group (NC) patients and patients with Alzheimer’s disease (AD), with mild cognitive impairment (MCI), and mild cognitive impairment converting to Alzheimer’s disease (MCIAD ) (a group of patients that clearly degrades to AD). We developed a voxelbased method for volumetric image analysis. We performed 3 classification experiments AD vs CG, AD vs MCI, MCIAD vs MCI. We will also give a small demonstration of the presented method on a set of face images. This method is capable to extract information about the location of metabolic changes induced by Alzheimer’s disease that directly relies statistical features and brain regions of interest (ROIs). We produce “maps” to visualize the most informative regions of the brain and compare them with voxel-wise statistics. Using the mean intensity of about 2000 6 × 6 × 6mm patches, selected by the extracted map, as input for a classifier we obtain a classification rate of 95.5%.
Export Options
About this article
Cite this article as:
Vigneron V., Kodewitz A., Tome M. A., Lelandais S. and Lang E., Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization, Current Alzheimer Research 2016; 13(5) . https://dx.doi.org/10.2174/1567205013666160314144822
DOI https://dx.doi.org/10.2174/1567205013666160314144822 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Chemical and Potential Biological Perspectives of Genus Sarcococca (Buxaceae)
The Natural Products Journal Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Editorial Review of 2014
Current Radiopharmaceuticals Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Lipids as Key Players in Alzheimer Disease - Alterations in Metabolism and Genetics
Current Alzheimer Research Expanded Temporal Binding Windows in People with Mild Cognitive Impairment
Current Alzheimer Research Antifungal Activity of 3-(heteroaryl-2-ylmethyl)thiazolidinone Derivatives
Medicinal Chemistry Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research Recent Developments in PET Instrumentation
Current Pharmaceutical Biotechnology Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form
Current Alzheimer Research Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
Current Radiopharmaceuticals Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Association of Amyloid Burden, Brain Atrophy and Memory Deficits in Aged Apolipoprotein ε4 Mice
Current Alzheimer Research From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus
Current Diabetes Reviews Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued)